ad image

Immuno-oncology Therapies

1 / 2
Activating the Immune System to Treat Cancer
Immuno-oncology

Activating the Immune System to Treat Cancer

Heat Biologics

PAO-01-22-R250-06Jan 26, 2022
Economically Viable, Same-Day Autologous Cell Therapies
Cell Therapy

Economically Viable, Same-Day Autologous Cell Therapies

Gregory Frost, Ph.D.; Sid Kerkar, M.D.

EXUMA Biotechnology

PAO-01-21-CL-06Feb 04, 2021
Astellas
M&A

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Astellas

PR-M01-20-NI-006Jan 03, 2020
Collaborating for Immunotherapy Development
Immunotherapy

Collaborating for Immunotherapy Development

KshitiJ (TJ) Ladage

Nice Insight

PAP-Q1-2019-NI-007Mar 12, 2019
Sanofi and Regeneron Immuno-oncology Collaboration Ending
Immuno-oncology

Sanofi and Regeneron Immuno-oncology Collaboration Ending

Nice Insight

PAO-M01-19-NI-012Jan 09, 2019
FIMECS, Inc.
Immuno-Oncology

FIMECS, Inc. Concludes Licensing Agreement with Takeda to Develop Novel Immuno-Oncology Therapies

FIMECS, Inc.

PR-M04-18-NI-44Apr 13, 2018
Allogene Therapeutics
Immuno-oncology

Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

Allogene Therapeutics

PR-M04-18-NI-40Apr 12, 2018
Boehringer Ingelheim
Immuno-Oncology

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership

Boehringer Ingelheim

PR-M04-18-NI-030Apr 10, 2018
Bristol-Myers Squibb
Immuno-Oncology

European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

PR-M01-18-NI-082Jan 25, 2018
Charles River Laboratories Continues to Grow Through Acquisition
Acquisition

Charles River Laboratories Continues to Grow Through Acquisition

Nigel Walker

Nice Insight

PAO-M01-18-NI-035Jan 19, 2018
Potenza Therapeutics, Inc.
Drug Development

Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Programs

Potenza Therapeutics, Inc.

PR-M01-18-NI-024Jan 10, 2018
Cue Biopharma
Business

Cue Biopharma Announces Closing of Initial Public Offering

Cue Biopharma

PR-M01-18-NI-003Jan 02, 2018
ARMO BioSciences, Inc
Immuno-Oncology Therapies

ARMO BioSciences Files Registration Statement for Proposed Initial Public Offering

ARMO BioSciences, Inc

PR-M01-18-NI-001Jan 02, 2018
Memory T Cells Fit to be Cross Trained
Drug Development

Memory T Cells Fit to be Cross Trained

Nice Insight

PAO-M12-17-NI-027Dec 19, 2017
Altering White Blood Cells to Kill Cancer
Oncology

Altering White Blood Cells to Kill Cancer

Nigel Walker

Nice Insight

PAO-M12-17-NI-026Dec 19, 2017
Bristol-Myers Squibb
Innovation

Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment

Bristol-Myers Squibb

PR-M12-17-NI-015Dec 15, 2017
Genentech and Biothera to Assess Combination Cancer Therapy
Immuno-oncology

Genentech and Biothera to Assess Combination Cancer Therapy

Nice Insight

PAO-M12-17-NI-010Dec 08, 2017
Immuno-oncology Approach Based on Electronic Circuitry
Immuno-oncology

Immuno-oncology Approach Based on Electronic Circuitry

Guy Tiene

Nice Insight

PAO-M11-17-NI-008Nov 03, 2017
Bristol-Myers Squibb Will Acquire IFM Therapeutics’ Innate Immune System Stimulators
Oncology

Bristol-Myers Squibb Will Acquire IFM Therapeutics’ Innate Immune System Stimulators

Nice Insight

PAO-M08-17-NI-015Aug 11, 2017
New Partnership Targets Colorectal Cancer with Combination Therapy, Including Avelumab
Drug Development

New Partnership Targets Colorectal Cancer with Combination Therapy, Including Avelumab

Guy Tiene

Nice Insight

PAO-M06-17-NI-020Jun 29, 2017
1 / 2